New gel aims to stop painful side effect of chemotherapy
NCT ID NCT07457671
First seen Mar 31, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a gel called TAR-0520 to prevent hand-foot syndrome, a painful skin reaction caused by the chemotherapy drug capecitabine. About 25 people with breast or colorectal cancer will apply the gel to their hands twice daily for 12 weeks. The goal is to see if the gel is safe and reduces the severity of hand-foot syndrome, improving quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAND AND FOOT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instiut Paoli-Calmettes
Marseille, 13009, France
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.